Abstract: CD4-mimetic HIV-1 entry inhibitors are small sized molecules which imitate similar conformational flexibility in gp120 as CD4 receptor, the mechanism of the conformational flexibility instigated by these small sized inhibitors, however, is little known. Likewise, the effect of the antibody on the function of these inhibitors is also less studied. In this study, we present a thorough inspection of the mechanism of the conformational flexibility induced by a CD4-mimetic inhibitor, NBD-557, using Molecular Dynamics Simulations and free energy 
Introductions: The pathogenic importance of human immunodeficiency virus type-1 (HIV-1)
is well known. [1] [2] [3] The HIV-1 infection is caused by the fusion of viral and host membranes in many sequential steps which are initiated by the non-covalent attachment of two regulatory subunits of HIV-1 envelope protein, gp120 and gp41. 4 A schematic view of these sequential steps can be comprehended by scheme1.
Scheme1.
A schematic representation of HIV-1 entry and fusion of virion into host membrane.
Initially, each unit of gp120 protein are arranged into homotrimeric fashion and form a closed cavity mushroom head-type system as shown in a, while the non-covalent binding of the gp41
protein with gp120 triggers some conformational changes that open a binding cavity for CD4
receptors and forms a complete mushroom shape, shown in b. [5] [6] The HIV-1 virion contains the RNA genome encapsulated by viral membrane where gp120.gp41 complexes are attached to the membrane surface and are exposed to the CD4 protein receptors of host membrane as shown in c. [7] [8] The docking of the virion via gp120 to the host membrane gives rise to the conformational rearrangement in the envelope protein that pulls viral membrane close to the CD4 subunits of host membrane, 9 shown in d. The binding of CD4 receptors via gp120 protein leads to more conformational changes and finally the fusion of host and viral membrane takes place, shown in e. As clear from the scheme 1, the gp120 is central to viral entry via binding to gp41 and CD4; it turns out to be the hot topic to target HIV-1 infections. The structural topography of gp120
revealed by X-ray crystallography shows two domains mixed of α-and β-motifs constitute the structure of gp120: the inner domain (residues 1-28, 44-95, 289-300) which interacts with gp41 protein, and outer and less conserved domain which interacts with CD4 and co-receptor (CR)
proteins (see Figure 1 for the structure of gp120) [10] [11] . Since the binding of gp120 with CD4 receptor proteins is the crucial step during HIV-1 infections, therefore, the site of CD4 binding in gp120 (scheme 1b) becomes a productive target for HIV-1 inhibition. [12] [13] [14] [15] The details and the recent development of these HIV-1 entry inhibitors targeting the gp120 proteins can be found in some nice review articles where we observe majority of the HIV-1 entry inhibitors are either BMS-378806 and its analogous or NBD-556 and its derivative. [16] [17] [18] Interestingly, these two inhibitors target same receptor but their mechanism is entirely different. An experimental study The instability of gp120 protein, when separated from its membrane anchored part, is a fundamental problem in getting the crystal structure of gp120. 4 with a typical example of NBD-557 with gp120. In order to achieve such study, we firstly emphasize the NBD-557 interactions and its binding thermodynamics without antibody and then compared the NBD-557 interaction and it's binding in the presence of antibody.
Methods:
2.1 System Setup: The initial structure was taken from protein data bank (PDB id: 4DVR) 20 which contains gp120 core, ligand NBD-557, and antibody Fab 48d. Since we have focused on the role of antibody on NBD-557 binding, we prepared two systems; one by extracting antibody and constructing a complex of ligand NBD-557 with gp120 only, and second as ligand NBD-557 with gp120 and antibody. The protonation state of Histidine residues was calculated by propka 3.0. 21 The pKa value for His54 was 6.72, therefore we kept it at doubly protonated state i.e. HIP, and rests of the Histidines were kept at either HIE (epsilon protonation) or HID (delta protonation) state depending upon the H-bond possibility with nearby residues. The missing hydrogens were prepared with Leap module of Amber 14 with Amber ff14SB forcefield parameters. 22 Since the parameters for NBD-557 were not available in Amber library, we used antechamber module of Amber to generate the parameters for NBD-557. The partial atomic charges and missing parameters for the NBD-557 were obtained from the RESP [23] [24] (Restrained electrostatic potential) method using HF/6-31G* geometry optimization by Gaussian 09 package.
We used five and two Cl -ions to neutralize the NBD-557 with gp120 only complex and the NBD-557 with gp120 and antibody complex, respectively. Finally, the resulting systems were solvated in a rectangular box of TIP3P 25 waters extending up to minimum cutoff of 10 Å from the protein boundary.
MD Simulations:
After proper parameterizations and setup, the resulting system's geometries were minimized (5000 steps for steepest descent and 10000 steps for conjugate gradient) to remove the poor contacts and relax the system. The systems were then gently annealed from 10 to 300 K under canonical ensemble for 50 ps with a weak restraint of 5 kcal/mol/Å 2 . Subsequently, the systems were maintained for 1 ns of density equilibration under isothermal-isobaric ensemble at target temperature of 300K and the target pressure of 1.0 atm using Langevin-thermostat 26 and
Berendsen barostat 27 with collision frequency of 2 ps and pressure relaxation time of 1 ps, with a weak restraint of 1 kcal/mol/Å 2 . Thereafter, we removed all restraints applied during heating and density dynamics and further equilibrated the systems for ∼3 ns to get well settled pressure and temperature for conformational and thermodynamical analyses. This was followed by a productive MD run of 100 ns for each system. During all MD simulations, the covalent bonds containing hydrogen were constrained using SHAKE, 28 and particle mesh Ewald (PME) 29 was used to treat long-range electrostatic interactions. We used an integration step of 2 fs during the entire simulations. All MD simulations were performed with GPU version of Amber 14 package. 30 
Clustering of the Trajectories
The energetic of ligand binding using end point method such as MMGB/SA (Molecular Mechanical Generalized Boltzmann/Surface Area) depends upon the selection of MD frames. 31 In this reference, clustering of trajectories provides an accurate way to represent the most statistically significant structures during MD sampling. Therefore, to facilitate most persistent conformations of the system during simulation, we performed clustering of MD trajectories using hieragglo algorithm implemented in Cpptraj of the Amber MD package for all complexes.
The clustering was done for the protein ligand complexes. In each case 10 clusters were generated. The results of the clustering are shown in Supplementary material.
Free energy Calculations
As stated by Schӧn et al, the antiviral properties of HIV-1 entry inhibitors are reflected by the thermodynamics of these inhibitors, we used MM-GB/SA method [32] [33] for the calculations of thermodynamic parameters and free energy of binding. The principles of these methods are well established [34] [35] and have been successfully applied for the class II fusion viruses in the previous studies [36] [37] [38] . Note that all energetics are calculated for the most populated frames of MD trajectories obtained from cluster analysis as described above. All water molecules and the chloride ions were stripped from the trajectory prior to the MMPBSA analysis. The dielectric constant for the solute and the surrounding solvents were kept 1 and 80 respectively. The MMPBSA calculations were performed on the most populated trajectories obtained from cluster analysis. All analysis of trajectories were done with the Cpptraj module of Amber14. VMD 1.6.7 39 , Chimera-1.5 40 graphical programs were used for the visualization. The hydrogen bonds and its occupancies were calculated by VMD for production trajectories where we kept donoracceptor distance as 3.0 Å and angle cut-off as 20 ⁰ .
Results and Discussion
We start with the conformational properties of gp120 complex with ligand NBD-557 when antibody is not binding; thereafter we discuss the conformational properties of gp120 complex with ligand NBD-557 when antibody is binding.
MD simulation of gp120 with NBD-557:
The RMS deviations (root mean square) with simulation time for the MD simulation of gp120
with NBD-557 are constant which shows a converged MD trajectory (see Figure S1 in supplementary materials). We also simulated gp120 only in absence of NBD-557 to study the Interestingly, Asn239 and Glu192 are residues situated at bridging interfaces between inner and outer domains and a disturbance at this site produces fluctuations at inner and outer domain end as seen in Figure 2a . For further validation of this mechanism, we performed another MD simulation of gp120 in absence of ligand and found a drastic decrement in thermal fluctuations in gp120 (see Figure 2b ). In this case, the binding between the Asn239 and Glu192 is rather weak due to absence of ligand which might be reason for the conformational elasticity of gp120 (see Figure S2 for Asn239-Glu192 distance). The lack of thermal fluctuations in absence of NBD-557 strongly supports the ligand instigated dynamics in gp120 which is factually caused by the interaction between NBD-557 and Asn239.
Thermo-chemistry of gp120 complex with NBD-557:
Schӧn et al reported the thermodynamics of binding of NBD-556 and NBD-557 with gp120 using ITC (Isothermal Titration Calorimetry). 19 They found the change in enthalpy during binding of NBD-556 (same as NBD-557) as -24.50 kcal/mol, and can be used to benchmark our simulated structure.
Therefore we calculated the change in enthalpy using the MMGBSA method for NBD-557 binding as shown in Table 1 . The computed change of enthalpy is -25.16±3.24 kcal/mol and is in good agreement with experimental results. 19 The theoretical calculation shows that the van der Waals interactions (-36.94 kcal/mol) plays a dominating role in enthalpic change during binding.
The electrostatic contribution is rather weak and is quite expected as NBD-557 forms just two hydrogen bonds with Glu 192 and Asn239. Furthermore, the interaction energy due to solvation has unfavourable contribution. To further emphasize the gp120-ligand interactions, we calculated the residue interaction map as shown in Figure 4 . The residue interaction map calculated by MMGBSA is very informative as non-polar and hydrophobic interactions cannot be analyzed similar to H-bond and salt-bridges.
We can see that Glu192 and Asn239 interact strongly with NBD-557 due to H bond as shown in 
Dynamics of the Asn239Gly Mutant:
Since NBD-557 interacts strongly with Asn239, we mutated Asn239 to Gly239 to monitor the effect of mutation on the gp120 complex.
Interestingly, the ligand remains quite stable. In the Asn239Gly mutant, the one of amine hydrogen (H1--N) of NBD-557 forms a very strong hydrogen bond with backbone oxygen of Glycine and doesn't show the switching of position as seen in WT complex (see Figure 5a,b) .
However, the Gly239 interaction with Glu192 is not as strong as in WT complex. The change in enthalpy of binding is more favourable vis-a-vis WT complex which clearly indicates that NBD-557 is a strong binder for the mutant complex (see Table S1 ). Figure 6 . We can easily notice the stability of the NBD-557 in gp120 with antibody relative to WT and Figure 6 . The RMS deviations for NBD-557 in all three MD simulations, i.e. with gp120, in Arg239Gly mutant and with antibody.
mutant. The change in enthalpy of binding is shown in Table 2 which quantitatively supports the enhanced binding affinity of drug due to antibody bonding. To decipher the rationale for the increased affinity due to antibody, we thoroughly studied the interactions between gp120 and antibody. We notice that residues 334-367 of antibody are proximal to gp120 interface and may interact with gp120. The interface between antibody and gp120 are rich of acidic residues such as Asp310, Asp334, Asp331, Asp334 at antibody site, and Arg149, Arg233, Lys235 and Lys246 at gp120 site which provide stability to the gp120 and antibody complex. The interaction energy of these residues, calculated by residue decomposition of MMPBSA is shown in Table 3 . These data quantitatively confirms that there are very strong acid-base pair interactions between gp120
and antibody interface such as Asp331-Arg233, Asp334-Arg233, Asp334-Lys235, Asp336-Lys235 and Asp336-Lys246 (See Figure 7 and Table 3 ). Table 1 for NBD-557
binding enthalpy in absence of antibody). Our calculations, shown in Table 4 , show that the 
Conclusions:
NBD-557 is a CD4 mimetic and its competitive receptor which is believed to induce similar conformational changes as CD4 receptor. Our MD simulations clearly show that NBD-557 induces large conformational flexibility, particularly in outer and inner domains. The absence of such flexibility in apo state of gp120 further substantiates the fact that such dynamics is mainly instigated by inhibitor, which was in good agreement with experimental observations. A thorough inspection of the simulated trajectories shows that interaction of NBD-557 with Asn239 is a key factor that choreographs the substrate ligand-induced conformational flexibility in gp120. The role of Asn239 was further supported by the MD simulations of N239G mutant.
We have found that the N239G mutation increases the binding affinity but it doesn't induce the flexibility in gp120 due to lack of flexible side chain interaction with NBD-557. The thermodynamical parameters of NBD-557 in presence of antibody shows enhanced binding enthalpy of inhibitors. We found that antibody possess many acidic residues at its gp120 facing interface which interacts strongly with basic residues of gp120 and thus provide an additional stability to the gp120.NBD-557 complex which in turn, increases the binding affinity of the complex. Our results from the MD simulations of the gp120 with antibody (Fab80) provide a theoretical validation that the antibody stabilizes the gp120 via crucial acid-base pairs at the binding interface between antibody and gp120. The binding free energy calculations quantitatively shows that antibody binding increases change in total binding energy via some conformational rearrangement in bridging sheet β20 which forms the active site for NBD-557
binding.
In summary, present study provide a comprehensive molecular mechanism of NBD-557 binding and how it mimics conformational rearrangement by CD4 co-receptor. Our study provides a theoretical validation of the fact that antibody stabilizes the gp120 and ligand binding. The mechanism of conformational changes instigated by NBD-557 and antibody can be useful for future studies for targeting HIV-1 entry.
